Jochen Müller’s Post

Embark on "The Fellowship of the Lab: An Epic Journey Beyond Academia's Gates" at the 11th Intercollegiate Biotechnology Symposium "Symbioza". This isn’t just a discussion; it’s a quest for knowledge, a bridge between worlds, a chance to forge your path from the hallowed halls of academia to the dynamic realms of industry. Have you ever spent long nights in the lab, wondering if your research could one day change the world? Dreamt of turning your scientific breakthroughs into market revolutions? If your heart says YES, then join us on this unparalleled adventure. Our fellowship comprises esteemed pioneers like Dr. Dagmar Ehrnhoefer, a vanguard at AbbVie battling Tau pathology in Alzheimer's disease, and Dr. Wojciech Buła, PhD, EMBA, a visionary who navigated the journey from academia to founding and leading groundbreaking startups like Bisu and ImmunoTronics, focusing on early sepsis detection technologies. This panel isn’t just about sharing stories; it's about crafting your own narrative in the saga of science and innovation. It’s an invitation to interact, question, and connect with the minds that have traversed the bridge between the lab bench and the boardroom, between theory and application. The clock is ticking, and the gates will close for onsite participation on April 14th. Don’t let this moment pass. Join our fellowship, discover the untold challenges and opportunities of academia-industry collaboration, and maybe, find your place in the legend. Forge your future, make your mark. Register now to ensure your chapter in this epic journey: https://lnkd.in/dXuAnTZ6

I am so excited to learning more about these technologies!

I hope you can join the team at #IndicaLabs for this informative webinar on highly multiplexed IF workflows with HALO, presented by Dr. Anne Hellebust, Director of Product, Life Sciences. Register today for the event on the 25th. I hope to see you there! #digitalpathology

We were thrilled  to participate in and support the recent Bio3 conference 2024 🎉 . A big thank you to Bio-Innovation Greece and the core organizing committee Georgia Kokaraki PhD, PMP, Nikos Kyrpides, Georgios Pavlopoulos, Michalis Hadjithomas for inviting us and for putting together such an outstanding event, bringing together a remarkable concentration  of knowledgeable individuals and groups from industry and academia. This initiative successfully united a diverse range of professionals from bioinformatics, biotech, and pharma. Through inspiring presentations and panel discussions it sparkled valuable conversations about the challenges faced by  both in the academia and industry offering fresh perspectives. We had  a great opportunity to expand our network, deepen our expertise, and share insights from our vision and work with the community. Highlights Booth: Our team engaged with numerous professionals at our booth, discussing our technical innovations and exchanging ideas with peers from both academia and industry. Special thanks 💚 to Aigli Korfiati, Afroditi Kravari, and Nikolaos Mourdoukoutas for their valuable contribution and continuous support. Presentation: Within the 4th day devoted to "AI in Drug Development" and the session chaired by Michalis Hadjithomas we attended 👀 exciting presentations from all speakers: Stavros Papadopoulos, Yiannis Kourmpetis, PhD, and Christina Koutsoumpa, PhD, elaborating on complementary aspects such as Tile-DB and multiomics databases, AI-assisted targeted innovation/ patent strategy, and medical imaging. Vassilis Pitsikalis took the stage to present our work in the area, emphasizing the importance on integrating interdisciplinary domain knowledge to develop trustworthy and interpretable AI models.  👉 Feel free to connect with us ! We look forward to understanding the challenges the community faces and building impactful collaborations to develop  effective real-world healthcare solutions. #Bio3 #MachineLearning #Bioinformatics #Biotechnology #Deeplab #BioInnovation

Illumina proudly announces the MiSeq i100! As the Optics Illumination Lead, I've been privileged to guide a diverse team of multi-disciplinary engineers, designing & developing the module from concept to product (it's inside the instrument, trust me lol). This program spanned the globe, across many timezones, all dedicated to creating this simple, accessible, and powerful sequencer. Since jumping into this project in 2020, there has been countless hours dedicated to ensuring its success. Despite the challenges of the pandemic, we've overcome obstacles and achieved significant milestones. With all the unknowns of how life will be during the early phase of the pandemic, I had many days & nights designing and simulating models, while breadboarding in the lab during the shutdowns. From not knowing what the future holds, to seeing everything come together during the prototype phases as we worked through the challenges, it's been a remarkable journey. The MiSeq i100 in general is a testament to our team's innovation and commitment. This low-throughput sequencer will democratize access to next-generation sequencing, enabling researchers to tackle critical questions in human health. With applications in cancer, pathogen, and viral research, the MiSeq i100 has the potential to revolutionize biotech and life sciences. #biotech #dnasequencing #genomics #lifescience #illumina

AI is making huge waves across all industries, and life sciences are no exception. But AI is a tool that is hungry for high dimensional data sets. High throughput technologies have been critical in allowing us to generate data in biology, but there are major bottlenecks if we want to create those data sets with patient derived cells. We need better tools! Join me at #SLAS2024, where I'll share how DropGenie is enabling discovery at the single patient resolution. I'll cover the most recent module we've built for #functionalgenomics and scientists that want to improve biological relevance earlier in drug discovery. Our solution leverages miniaturization and parallelization in modules that can seamlessly plug into automation ecosystems. It's at the end of the day, but I promise it's worth waiting for :) Date: Monday February 5th, 4:30-5:00pm Track: Assay Development and Screening,Session: (107) Room: 205ABC

The one month countdown is on! Come see the latest microscale innovations and learn how you can apply them within your research. https://lnkd.in/e_2nR23p

Great news can be re-shared! In January, ERC announced awardees of the last round of 2023 Proof of Concept grants. Four of these were Swedish, of which two SciLifeLab Group leaders and #fellow alumni ⭐ Ilaria Testa and ⭐ Tanja Slotte. Warmest congratulations, and very much look forward to hearing more about the results of these exciting projects: #DiffusOMICS; A new technology to probe molecular interaction in cells at high throughput, and #AdaptiveTarget, Accessing haplotype variation at complex loci with optimized targeting and adaptive sampling https://lnkd.in/d8Ffj78R

Are you going to the European Workshop on Drug Design? Optibrium's Alessia Centi will be leading a workshop on in silico prediction of Phase I and II metabolism: guiding optimisation of drug metabolism. Make sure you sign up to find out more about: 👉How to design new compounds for greater metabolic stability 👉How to find the routes and products of metabolism, with a goal of reducing risks of drug-drug interactions, issues due to genetic polymorphisms, or the formation of reactive or toxic metabolites 👉How to identify the most important enzymes for coverage during preclinical studies For further information on the workshop, visit https://lnkd.in/eBK-Kg2B

🌟 Exciting Research Collaboration Alert! 🌟 We are glad to announce that Simão Santos from Lammertyn lab ( Department of Biosystems ) started a 3-month research stay at the Interfibio group under the supervision of Dr. Ciara O' Sullivan and Dr. Vasoula Skouridou. During this period, Simão will be working on groundbreaking projects to develop RPA assays and nucleic acid-based lateral flow assays (NALFA) aimed at detecting female-specific genes in allantoic fluid. His work will focus on: 🔬 Optimizing RPA reaction parameters 🔬Designing tailed primers for NALFA 🔬 Refining the assay to work with minimal sample and buffer volumes Once fully developed, the NALFA will “suit like a glove” the SIMPLE microfluidic chip Simão has been developing during his PhD, paving the way for a fully autonomous microfluidic platform for in ovo sexing. We are excited to see the innovative advancements that will come from this collaboration. Best of luck, Simão! 🚀 #Research #Innovation #Collaboration #Microfluidics #Biotechnology #InOvoSexing